Eli Lilly and Company
TIGIT AND PD-1/TIGIT-BINDING MOLECULES
Last updated:
Abstract:
The present invention relates to polypeptide molecules that bind to human TIGIT, and to polypeptide molecules that bind to human PD-1 and human TIGIT, and are useful for treating solid tumors, alone and in combination with chemotherapy and/or ionizing radiation.
Status:
Application
Type:
Utility
Filling date:
22 May 2020
Issue date:
21 Jul 2022